Y-MABS THERAPEUTICS INC. - COMMON STOCK

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 يناير 2025 09:26:05 بحسب Nasdaq GlobeNewswire

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

10 يناير 2025 07:35:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 يناير 2025 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 ديسمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

07 ديسمبر 2024 12:00:00 بحسب Nasdaq GlobeNewswire

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

27 نوفمبر 2024 07:35:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

08 نوفمبر 2024 06:35:00 بحسب Nasdaq GlobeNewswire

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

04 نوفمبر 2024 07:35:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

25 أكتوبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in October

01 أكتوبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

06 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in September

03 سبتمبر 2024 08:32:32 بحسب Nasdaq GlobeNewswire

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

12 أغسطس 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in August

07 أغسطس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

05 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

01 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

07 يونيو 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

05 يونيو 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

01 يونيو 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

01 يونيو 2024 08:05:00 بحسب Nasdaq GlobeNewswire